trending Market Intelligence /marketintelligence/en/news-insights/trending/6dGehkxaT70Gk4n-HIryRQ2 content esgSubNav
In This List

Emerald Health closes investment in Abattis Bioceuticals unit

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Emerald Health closes investment in Abattis Bioceuticals unit

Emerald Health Therapeutics Inc. completed its previously announced acquisition of a 53% interest in Northern Vine Canada Inc., a unit of Abattis Bioceuticals Corp.

Emerald Health invested C$2.5 million into Northern Vine for the ownership interest. The company will also appoint three of its four directors.

Abattis will continue to own the remaining 47% of Northern Vine.